$KRYS gets more skin in the epidermolysis bullosa game. I spoke to the company ahead of more data with its unusual topical gene therapy candidate KB103. Via Vantageanalysis httpsbit.ly2SNLdYwÂ

$KRYS gets more skin in the epidermolysis bullosa game. I spoke to the company ahead of more data with its unusual topical gene therapy candidate, KB103. Via @Vantageanalysis https://bit.ly/2SNLdYw 

11:50 EST 5 Mar 2019 | Odi Bruckman

$KRYS gets more skin in the epidermolysis bullosa game. I spoke to the company ahead of more data with its unusual topical gene therapy candidate, KB103. Via @Vantageanalysis https://bit.ly/2SNLdYw 

More From BioPortfolio on "$KRYS gets more skin in the epidermolysis bullosa game. I spoke to the company ahead of more data with its unusual topical gene therapy candidate, KB103. Via @Vantageanalysis https://bit.ly/2SNLdYw "